An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

NCT01137006 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: IMC-20D7S (Cohort 1A)
BIOLOGICAL: IMC-20D7S (Cohort 2A)
BIOLOGICAL: IMC-20D7S (Cohort 3A)
BIOLOGICAL: IMC-20D7S (Cohort 4A)
BIOLOGICAL: IMC-20D7S (Cohort 1B)
BIOLOGICAL: IMC-20D7S (Cohort 2B)
BIOLOGICAL: IMC-20D7S (Cohort 3B)

Sponsor

Eli Lilly and Company